Number of Patients Screened for Enrollment by Pathology Assessment
| . | CTCL No. (%) . | HD No. (%) . | NHL No. (%) . | All No. (%) . |
|---|---|---|---|---|
| Total Screened | 105 | 37 | 88 | 230 |
| No tumor found | 9 | 3 | 7 | 19 |
| No immunophenotyping done (No frozen specimen submitted) | 3 | 10 | 6 | 19 |
| IL-2R positive | 58 (62) | 21 (78) | 30 (40) | 109 (57) |
| P55 only | 33 | 11 | 25 | 69 |
| P75 only | 6 | 0 | 0 | 6 |
| Both | 19 | 10 | 5 | 34 |
| IL-2R indeterminate | 8 | 2 | 3 | 13 |
| IL-2R undetected | 27 | 2 | 41 | 70 |
| Patients enrolled | 35 | 21* | 17 | 73* |
| Percent of patients found to be IL-2R positive who were enrolled | (60) | (70)* | (55) | (67) |
| . | CTCL No. (%) . | HD No. (%) . | NHL No. (%) . | All No. (%) . |
|---|---|---|---|---|
| Total Screened | 105 | 37 | 88 | 230 |
| No tumor found | 9 | 3 | 7 | 19 |
| No immunophenotyping done (No frozen specimen submitted) | 3 | 10 | 6 | 19 |
| IL-2R positive | 58 (62) | 21 (78) | 30 (40) | 109 (57) |
| P55 only | 33 | 11 | 25 | 69 |
| P75 only | 6 | 0 | 0 | 6 |
| Both | 19 | 10 | 5 | 34 |
| IL-2R indeterminate | 8 | 2 | 3 | 13 |
| IL-2R undetected | 27 | 2 | 41 | 70 |
| Patients enrolled | 35 | 21* | 17 | 73* |
| Percent of patients found to be IL-2R positive who were enrolled | (60) | (70)* | (55) | (67) |
*Initially patients with HD were not required to have tumor IL-2R confirmation as many of these patients present with disease sites not readily accessible for biopsy. This provision was modified by amendment after 7 HD patients were enrolled. The remaining 14 HD patients enrolled after the amendment were IL-2R positive.